Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 + Fulvestrant in ER+/HER2- Metastatic Breast Cancer
NCT02374099Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Mar 2015
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of CC-486 in breast cancer, sponsored by Celgene Corporation. Started Mar 2015; status: terminated.
02
Drugs
CC-486
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02374099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374099.